Thursday greetings to you all, with Andrew Joseph right here in London filling in for Mr. Pharmalot. Our cups of stimulation this morning now seem to be a distant dream, however alas, there’s no choice different than simply powering by. Listed below are some tidbits for no matter time it’s in your day. …
Roche reported higher than anticipated first-half working revenue, pushed by robust gross sales of breast most cancers and bronchial asthma remedies, Reuters tells us. Revenues from breast most cancers drug Phesgo and bronchial asthma and meals allergy symptoms drugs Xolair each got here in above forecast, although the Swiss pharma’s intently watched Vabysmo, to counter a standard type of blindness within the aged, got here in barely beneath expectations. Diagnostics division gross sales have been secure, the corporate mentioned, as rising demand for pathology options and blood screening exams offset the impact of China’s well being care pricing reforms.
In the meantime, Roche additionally introduced that it was weighing direct-to-patient drug gross sales within the U.S., bypassing middlemen for its dear medicines for a number of sclerosis, eye illness, and most cancers, per Bloomberg. The corporate has mentioned such a program with the U.S. authorities, with CEO Thomas Schinecker saying the transfer would deliver down prices “fairly rapidly.” Different corporations together with Pfizer, Eli Lilly, and Novo Nordisk have began promoting medicines through telehealth to shoppers, partly to bypass gamers like pharmacy profit managers.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
